Category - Developments

Developments

bioAffinity initiates longitudinal study for CyPath Lung

bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has initiated a planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000...

March 11, 2026

Developments

ACCP Journal publishes PK studies of Tonix’s TONMYA in fibromyalgia

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced that the American College of Clinical Pharmacology (ACCP) journal Clinical Pharmacology in Drug Development published results from clinical pharmacokinetic (PK) studies...

March 6, 2026

Developments

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co...

March 6, 2026

Developments

INOVIO and Akeso collaborate to advance GMB therapy

INOVIO (NASDAQ: INO) and Akeso (HKEX: 9926) have announced a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO’s DNA immunotherapy candidate, in combination with cadonilimab...

March 4, 2026

Developments

Firefly nears launch of NVIDIA-powered human brain model

Firefly Neuroscience (NASDAQ: AIFF) has announced a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes. Through its acquisition of closely held Evoke...

March 4, 2026

Developments

FDA approves Perimeter’s Claire, first AI imaging device for breast cancer surgery

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has received FDA premarket approval (PMA) for Claire—formerly the Perimeter OCT B-Series with ImgAssist AI 2.0—the first AI-enabled imaging...

March 3, 2026

Developments

Psyence ships GMP-compliant psilocybin to Australia for Phase 2b trial

Psyence BioMed (NASDAQ: PBM) has announced the export of fully GMP-compliant manufactured psilocybin product NPX-5 to Australia for the ongoing Phase 2b clinical trial evaluating natural psilocybin for the treatment of...

March 3, 2026

Developments

Rein doses first patient in Phase 2 trial of LTI-03 in IPF

Rein Therapeutics (NASDAQ: RNTX) has announced that the first patient has been dosed in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with...

March 3, 2026

Developments

AIM signs Phase 3 design deal for Ampligen in pancreatic cancer

AIM ImmunoTech (NYSE American: AIM) has announced the signing of an agreement with Thermo Fisher Scientific’s (NYSE: TMO) PPD clinical research business to design its Phase 3 clinical trial for Ampligen in the treatment...

March 2, 2026

Developments

Zomedica expands distribution with Moichor partnership

Zomedica (OTCQB: ZOMDF) has entered into a commercial distribution agreement with closely held Moichor, a veterinary reference and point-of-care laboratory service, to expand its distribution of TRUVIEW(R) digital...

February 25, 2026

Category - Developments

Subscribe